Some features of the course of arterial hypertension in patients undergoing a new coronavirus infection (COVID-19)

The aim of the study was to analyze the incidence of arterial hypertension among comorbidities in patients with coronavirus infection, to consider the effect of coronavirus infection on the course of cardiovascular diseases according to instrumental diagnostic methods. Materials and methods: theoretical (analysis and synthesis of studies on the problem); empirical (observation, interviews); methods of quantitative data processing. Results of the study. Based on the analysis of the literature, our own observation and management of patients with arterial hypertension who had new coronavirus infection (COVID 19), we can suggest that therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers should be continued and their withdrawal during the pandemic is not justified, since at present there are no compelling data to discontinue therapy with renin-angiotensin-aldosterone system blockers to prevent infection or Conclusion. To date, there is no proven theory about the role of the renin-angiotensin-aldosterone system and its blockers in the development of complications and outcomes of coronavirus infection, and drugs from the groups of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Are still vital drugs that determine the prognosis for patients with arterial hypertension, chronic heart failure, coronary heart disease, for those with diabetes, and discontinuation of treatment can have extremely adverse effects, including increased mortality. And the group of patients with concomitant cardiovascular diseases, long-term recipients of drugs from the group of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, should be considered, “as a risk group requiring more careful monitoring of the condition” with confirmed SARS-CoV-2 infection.